These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Trimetazidine effects on postinfarction remodeling of the left ventricle].
    Author: Kokov AN, Tarasov II, Barbarash LS.
    Journal: Ter Arkh; 2005; 77(8):10-4. PubMed ID: 16206598.
    Abstract:
    AIM: To study effects of combined therapy including trimetazidine on morphofunctional indices of the left ventricle (LV). MATERIAL AND METHODS: Seventy five patients with primary macrofocal myocardial infarction (MI) were randomized into two groups: 38 patients of group 1 received combination of bisoprolol, a beta-adrenoblocker, and analapril, an ACE inhibitor, in individually adjusted dose under control of blood pressure (BP) and blood creatinine; 37 patients of group 2 received the same combination and trimetazidine in a dose 70 mg/day for 6 months beginning on postinfarction day 7-10. Each group contained a subgroup treated with systemic thrombolytic streptokinase at admission. MR imaging (MRI) and cine-MRI assessed morphofunctional L V parameters. RESULTS: A 6-month therapy with trimetazine resulted in a significant regress of the morphofunctional alterations associated with LV remodeling in postmyocardial infarction patients. CONCLUSION: Combined treatment including systemic thrombolysis with streptokinase within MI hours 0-6, trimetasidine on MI day 7-10 plus 6 months significantly inhibits pathological postinfarction LV remodeling.
    [Abstract] [Full Text] [Related] [New Search]